![]() Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ. ![]() In this review we discuss the mechanism of action of T-DM1 and the key clinical results obtained with it, the combinations ofT-DM1 with other cytotoxic agents and anti-HER drugs, and the potential resistance mechanisms and the strategies to overcome resistance to T-DM1. The effect ofT-DM1 may also be compromised by multidrug resistance proteins that pump DM1 out of cancer cells. The cytotoxic effect of T-DM1 may be impaired by inefficient internalization or enhanced recycling of the HER2-T-DM1 complex in cancer cells, or impaired lysosomal degradation of trastuzumab or intracellular trafficking of HER2. The mechanisms of resistance are incompletely understood, but mechanisms limiting the binding of trastuzumab to cancer cells may be involved. Primary resistance of HER2-positive metastatic breast cancer to T-DM1 appears to be relatively infrequent, but most patients treated with T-DM1 develop acquired drug resistance. The cytotoxic effect of T-DM1 likely varies depending on the intracellular concentration of DM1 accumulated in cancer cells, high intracellular levels resulting in rapid apoptosis, somewhat lower levels in impaired cellular trafficking and mitotic catastrophe, while the lowest levels lead to poor response to T-DM1. It has several mechanisms of action consisting of the anti-tumor effects of trastuzumab and those of DM1, a cytotoxic anti-microtubule agent released within thetarget cells upon degradation of the human epidermal growth factor receptor-2 (HER2)-T-DM1 complex in lysosomes. T-DM1 is currently being evaluated as adjuvant treatment for early breast cancer. Efficacy has now been demonstrated in randomized trials as first line, second line, and later than the second line treatment of advanced breast cancer. Send us an email at Include photos of item/s and give proof of your claim of the item not being authentic.Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that is effective and generally well tolerated when administered as a single agent to treat advanced breast cancer. Send us an email at State the missing parts and include a screenshot of these for reference. Item should be shipped back to Galleon within seven (7) calendar days upon receipt of the item Product is malfunctioning or is defective when it arrives Send us an email at Include videos of item/s showing item damage/defect. Item should be shipped back to Galleon within seven (7) calendar days upon receipt of the item. At 12 grams, it might be the lighest wallet you'll ever own! There are no screws, hinges, snaps, magnets, straps or rubber bands to break. Our products are CNC Machined in the USA from a single billet of 6061-T6 Aircraft-Grade Aluminum. At only 3.53Ó x 2.38Ó x 0.23Ó, it is thinner than an iPhone 6 and just barely larger than a credit card. The open front and back are ideal for photo ID cards like a drivers license. It does NOT block RFID Ð so you can use building access cards and contact-less RFID credit cards without removing them from the DM1. The design eliminates any unnecessary parts, but securely and beautifully carries and protects your cards. Made from a single piece of aluminum, cut into the ideal shape to positively retain as few as 1 and up to 8 identification or credit cards. Securely holds up to 8 ID or credit cardsĪbout Decadent Minimalist Men's DM1 Aluminum Wallet Decadent Minimalist Men's DM1 Aluminum Wallet Features
0 Comments
Leave a Reply. |